BioArctic’s partner Eisai launches Leqembi in South Korea to treat MCI due to AD or mild AD dementia: Stockholm, Sweden Friday, November 29, 2024, 16:00 Hrs [IST] BioArctic ABs ...

Advances in immunotherapy have ushered in a new era of treatment for follicular lymphoma (FL), particularly for patients who have experienced relapse ...

Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea.

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

BioArctic AB's (publ) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea in May 2024 for treatment ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Report with market evolution powered by AI - The global gastroparesis drugs market size is estimated to grow by USD 1.42 ...

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...

Eisai and the National Center of Neurology and Psychiatry in Tokyo will study the link between APOE genotype and safety and efficacy of Leqembi.

The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...

Anavex Life Sciences (AVXL) stock rises 10% in premarket as company submits EU marketing application for Alzheimer's drug ...

Brain Tumor Drugs Market To Reach USD 5.25 Billion By 2032, Driven By Advances In Targeted Therapies And Immunotherapies Increasing demand for personalized treatment approaches & the growing ...